A Risky Drug Approval Lesson

Some welcome news arrived recently for boys with a condition called Duchenne muscular dystrophy. A new therapy is showing promising results, and it raises a question for the Food and Drug Administration: What if society had missed this moment? In late June Sarepta Therapeutics , a biotech company, …